← Dizal (Jiangsu) Pharmaceutical Co. Ltd. A overview

Dizal (Jiangsu) Pharmaceutical Co. Ltd. A vs Sichuan Kelun Pharmaceutical: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Dizal (Jiangsu) Pharmaceutical Co. Ltd. A (688192.CG)

Q3 2026
▲3▼1

AstraZeneca $1.5B Deal and Strong H1 Results Drive Dizal Higher

  • AstraZeneca $1.5B Licensing Deal Dizal licensed worldwide rights to lung cancer drug Zegfrovy to AstraZeneca for up to $1.5B, including $600M upfront. The stock hit its 20% daily limit twice as investors cheered the deal.

    This landmark deal was the primary catalyst for the stock's surge during the quarter.

  • Improved Financials and Insurance Coverage H1 2026 revenue rose 47% to RMB523M, losses narrowed by RMB167M, and the $600M upfront payment eased funding concerns. National insurance coverage boosted sales.

    Strong financial results and improved cash position reinforced investor confidence.

  • Pipeline Progress and Sector Momentum Birecitinib Phase II data showed a 47.6% response rate, adding pipeline value. Record out-licensing deals in the sector lifted sentiment across biotech stocks.

    Pipeline success and favorable sector trends contributed to the stock's upward movement.

  • Regulatory Risks Remain The AstraZeneca deal still requires antitrust clearance and closing conditions in H2 2026. Delays or a block could hurt the stock, posing a real counterweight to recent gains.

    This risk could reverse gains if the deal fails to close, providing a balanced view.

September 2026
▲4

AstraZeneca's $600M upfront transforms Dizal's finances and global reach

  • AstraZeneca $600M upfront payment received Dizal received $600 million upfront from AstraZeneca for global rights to sunvozertinib, strengthening cash reserves and expected to boost 2026 results. This removes funding concerns and validates the drug's potential, supporting the stock price.

    This is the core new event that directly improves Dizal's financial position and growth outlook.

  • First-half revenue up 47%, losses narrowed Dizal's H1 2026 revenue rose 47% to 523 million yuan, with net loss narrowing by 167 million yuan. Both core drugs are now on China's national insurance list, driving domestic sales and improving profitability.

    Shows improving operational performance and commercial traction, a key driver of investor confidence.

  • Birecitinib Phase II data published Phase II study of birecitinib in relapsed/refractory DLBCL showed 47.6% overall response rate and 31% complete response rate. Publication in a medical journal validates the drug's potential, adding pipeline value and future revenue prospects.

    Highlights pipeline progress that could drive long-term growth and diversify revenue.

  • Sector sentiment boosted by licensing deals Hengrui's $2.6B deal with Novo Nordisk and Dizal's AstraZeneca payment lifted the healthcare sector, with the STAR Market Biomedical Index up nearly 3%. Positive sector momentum can attract more investors to Dizal.

    Captures the broader market reaction that amplifies Dizal's stock movement.

Latest
▲4

AstraZeneca's $600M upfront transforms Dizal's finances and global reach

  • AstraZeneca $600M upfront payment received Dizal received $600 million upfront from AstraZeneca for global rights to sunvozertinib, strengthening cash reserves and expected to boost 2026 results. This removes funding concerns and validates the drug's potential, supporting the stock price.

    This is the core new event that directly improves Dizal's financial position and growth outlook.

  • First-half revenue up 47%, losses narrowed Dizal's H1 2026 revenue rose 47% to 523 million yuan, with net loss narrowing by 167 million yuan. Both core drugs are now on China's national insurance list, driving domestic sales and improving profitability.

    Shows improving operational performance and commercial traction, a key driver of investor confidence.

  • Birecitinib Phase II data published Phase II study of birecitinib in relapsed/refractory DLBCL showed 47.6% overall response rate and 31% complete response rate. Publication in a medical journal validates the drug's potential, adding pipeline value and future revenue prospects.

    Highlights pipeline progress that could drive long-term growth and diversify revenue.

  • Sector sentiment boosted by licensing deals Hengrui's $2.6B deal with Novo Nordisk and Dizal's AstraZeneca payment lifted the healthcare sector, with the STAR Market Biomedical Index up nearly 3%. Positive sector momentum can attract more investors to Dizal.

    Captures the broader market reaction that amplifies Dizal's stock movement.

July 2026
▲3▼1

Dizal's $1.5B AstraZeneca deal drives record rally

  • AstraZeneca global license deal worth up to $1.5B Dizal granted AstraZeneca worldwide rights to its lung cancer drug Zegfrovy. Dizal gets $600 million upfront and up to $900 million more if milestones are met, plus royalties. This huge cash infusion validates the drug and boosts investor confidence.

    This is the core new event that directly explains the stock's surge.

  • Stock hits 20% daily limit for two straight days Dizal shares surged by the maximum 20% allowed on both July 14 and 15, reflecting intense buying. The rally was part of a broader innovative drug sector boom, but Dizal stood out due to its record licensing deal.

    Shows the immediate market reaction to the deal and the stock's momentum.

  • Sector-wide policy support and record out-licensing trend New healthcare policies, including the 15th Five-Year Plan and updated essential medicines list, are boosting the entire innovative drug sector. Chinese drug out-licensing deals hit a record $110 billion in H1 2026, with Dizal among the top deals.

    Provides the broader context that amplifies the impact of Dizal's deal.

  • Deal still subject to closing conditions and antitrust approval The AstraZeneca agreement is expected to close in the second half of 2026, pending customary conditions and regulatory clearances. There is a risk the deal could be delayed or blocked, which could hurt the stock if it falls through.

    Highlights a real counterweight that investors should consider.

▲3▼1

Dizal's $1.5B AstraZeneca deal drives record rally

  • AstraZeneca global license deal worth up to $1.5B Dizal granted AstraZeneca worldwide rights to its lung cancer drug Zegfrovy. Dizal gets $600 million upfront and up to $900 million more if milestones are met, plus royalties. This huge cash infusion validates the drug and boosts investor confidence.

    This is the core new event that directly explains the stock's surge.

  • Stock hits 20% daily limit for two straight days Dizal shares surged by the maximum 20% allowed on both July 14 and 15, reflecting intense buying. The rally was part of a broader innovative drug sector boom, but Dizal stood out due to its record licensing deal.

    Shows the immediate market reaction to the deal and the stock's momentum.

  • Sector-wide policy support and record out-licensing trend New healthcare policies, including the 15th Five-Year Plan and updated essential medicines list, are boosting the entire innovative drug sector. Chinese drug out-licensing deals hit a record $110 billion in H1 2026, with Dizal among the top deals.

    Provides the broader context that amplifies the impact of Dizal's deal.

  • Deal still subject to closing conditions and antitrust approval The AstraZeneca agreement is expected to close in the second half of 2026, pending customary conditions and regulatory clearances. There is a risk the deal could be delayed or blocked, which could hurt the stock if it falls through.

    Highlights a real counterweight that investors should consider.

Sichuan Kelun Pharmaceutical Co Ltd (002422.CS)

Q3 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

September 2026
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.

Latest
▲3▼1

Kelun's profit rises on drug wins and buybacks, but bribery claim and pledges weigh

  • New ADC drug enters clinical trials A Kelun subsidiary won Chinese approval to start human testing of SKB565, a new dual-payload ADC for advanced solid tumors. It is the first of its kind from Kelun Biotech, and success could add a valuable future growth engine, though it is years from sales.

    Shows pipeline progress that can lift long-term growth expectations for the stock.

  • National procurement wins boost sales outlook Kelun and its units won tentative selection for more than ten products in China's 12th national bulk-buy drug round, including heart and cancer medicines. Winning means guaranteed hospital sales volumes, supporting revenue even if prices are lower.

    Directly increases expected product demand and market share, a core earnings driver.

  • Profit grows and dividend plus buyback support stock First-half net profit rose 12.7% to 1.128 billion yuan, with second-quarter profit up 48% from the prior quarter, despite slightly lower revenue. The company also plans a cash dividend and has been buying back shares, signaling confidence and returning cash to holders.

    Earnings growth and shareholder returns are the main fundamental supports for the share price.

  • Bribery claim and owner pledges create risk A whistleblower letter alleged commercial bribery tied to a key Kelun drug; the subsidiary denies it and threatens legal action. Separately, controlling shareholder Liu Gexin added to pledged shares for personal funding. Both raise uncertainty and could pressure the stock if they worsen.

    These are the main counterweights that could hurt sentiment and valuation.